These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

10914 related articles for article (PubMed ID: 10082396)

  • 1. Apoptosis, Fas and Fas-ligand expression in melanocytic tumors.
    Sprecher E; Bergman R; Meilick A; Kerner H; Manov L; Reiter I; Shafer Y; Maor G; Friedman-Birnbaum R
    J Cutan Pathol; 1999 Feb; 26(2):72-7. PubMed ID: 10082396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
    Bergman R; Kerner H; Manov L; Friedman-Birnbaum R
    Am J Dermatopathol; 1998 Jun; 20(3):262-5. PubMed ID: 9650699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi.
    Florell SR; Bowen AR; Hanks AN; Murphy KJ; Grossman D
    J Cutan Pathol; 2005 Jan; 32(1):45-9. PubMed ID: 15660660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas.
    Bergman R; Azzam H; Sprecher E; Manov L; Munichor M; Friedman-Birnbaum R; Ben-Itzhak O
    J Am Acad Dermatol; 2000 Mar; 42(3):496-500. PubMed ID: 10688724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
    Shukuwa T; Katayama I; Koji T
    Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent downregulation of Fas (CD95) expression and function in melanoma.
    Bullani RR; Wehrli P; Viard-Leveugle I; Rimoldi D; Cerottini JC; Saurat JH; Tschopp J; French LE
    Melanoma Res; 2002 Jun; 12(3):263-70. PubMed ID: 12140383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
    Googe PB; Flanigan KL; Miedema JR
    Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
    Piris A; Mihm MC; Hoang MP
    Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
    Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
    J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
    Isabel Zhu Y; Fitzpatrick JE
    J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
    Nagasaka T; Lai R; Medeiros LJ; Brynes RK; McCourty A; Harada T; Saddik M
    Am J Dermatopathol; 1999 Apr; 21(2):115-20. PubMed ID: 10218669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
    Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
    Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.
    Krengel S; Grotelüschen F; Bartsch S; Tronnier M
    J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis.
    Terheyden P; Siedel C; Merkel A; Kämpgen E; Bröcker EB; Becker JC
    J Invest Dermatol; 1999 Jun; 112(6):899-902. PubMed ID: 10383736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
    Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
    J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
    Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
    Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 546.